What it's for (Indications)
- Calcium dobesilate is primarily indicated for the management of disorders related to capillary resistance and permeability.
- Its principal applications include the treatment of microangiopathies, such as diabetic retinopathy, which affects the blood vessels in the retina, and diabetic nephropathy, involving kidney damage due to diabetes.
- It is also prescribed for chronic venous insufficiency, a condition where leg veins struggle to return blood to the heart, manifesting as symptoms like edema, pain, heaviness in the legs, trophic disorders, and leg ulcers.
- Furthermore, it can be used for symptomatic treatment of hemorrhoidal syndrome and to address capillary fragility disorders where there is an increased tendency for bleeding or bruising due to weakened capillaries.
- The therapeutic goal is to improve microcirculatory function and alleviate associated symptoms by normalizing capillary permeability and resistance.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of calcium dobesilate must be determined by a qualified healthcare professional, considering the specific medical condition being treated, its severity, and individual patient response and tolerance. Typically, for conditions such as chronic venous insufficiency or diabetic retinopathy, the usual oral dosage ranges from 500 mg to 1000 mg per day. This daily dose is generally administered in two or three divided doses, often with meals to minimize potential gastrointestinal discomfort. For example, a common regimen might involve one 500 mg capsule taken twice daily. In certain acute presentations, such as severe hemorrhoidal crises, a higher initial dose might be considered for a short period before reducing to a maintenance dose. Treatment duration can vary significantly, often extending over several weeks or months to achieve optimal therapeutic benefits and prevent recurrence. Adherence to the prescribed dosage and duration is crucial for effective management and to mitigate potential risks associated with therapy. |
Safety & Warnings
Common Side Effects
- Calcium dobesilate is generally well-tolerated, but like all medications, it can cause adverse effects, although these are typically mild and transient.
- Common side effects often involve the gastrointestinal system and may include nausea, diarrhea, abdominal discomfort, or stomach upset.
- Skin reactions such as rash, pruritus (itching), or urticaria (hives) have also been reported in some individuals.
- Other less common side effects can include headache, arthralgia (joint pain), and fatigue.
- While rare, more severe adverse reactions have been documented, most notably agranulocytosis, a serious blood disorder characterized by a severe reduction in white blood cells (neutrophils), which can compromise the body's ability to fight infection.
- This rare but serious event necessitates immediate medical attention.
- Patients should be advised to report any unusual or persistent symptoms to their healthcare provider promptly.
Serious Warnings
- Black Box Warning: While calcium dobesilate does not possess a formal 'Black Box Warning' issued by regulatory bodies such as the U.S. Food and Drug Administration (FDA) due to its limited market presence in the US, it is imperative to provide a serious and prominent safety warning concerning the rare but potentially life-threatening adverse effect of agranulocytosis. Agranulocytosis is a severe reduction in granulocytes (a type of white blood cell), which can significantly impair the body's immune response and lead to severe, overwhelming infections. Patients receiving calcium dobesilate must be thoroughly educated on the signs and symptoms of agranulocytosis, including fever, flu-like symptoms (e.g., malaise, fatigue, body aches), sore throat, oral lesions, and unusual bleeding or bruising. Should any of these symptoms develop, the patient must immediately discontinue the medication and seek urgent medical attention. A complete blood count (CBC) with differential must be performed without delay to confirm or rule out agranulocytosis. If confirmed, calcium dobesilate must be permanently discontinued, and appropriate medical management for agranulocytosis initiated. This serious risk mandates vigilant patient monitoring and prompt intervention to prevent severe outcomes. Patients with a history of agranulocytosis, irrespective of cause, should not be prescribed calcium dobesilate.
- This section outlines critical safety information for calcium dobesilate, emphasizing potential serious adverse events that necessitate careful patient monitoring and immediate intervention.
- While calcium dobesilate does not carry a formal FDA Black Box Warning (as it is not extensively marketed or FDA-approved in the United States), it is imperative to highlight the very rare but life-threatening risk of agranulocytosis.
- Agranulocytosis is a severe reduction in granulocytes, a type of white blood cell, leading to profound immunosuppression and increased susceptibility to severe infections.
- Patients should be explicitly instructed to discontinue the medication immediately and seek urgent medical evaluation if they experience symptoms indicative of agranulocytosis, such as fever, flu-like symptoms (e.
- g.
- , general malaise, weakness), sore throat, tonsillitis, or oral lesions.
- A complete blood count (CBC) with differential should be performed promptly to assess neutrophil levels.
- Treatment should not be re-initiated if agranulocytosis is confirmed.
- Caution is also advised in patients with pre-existing renal impairment, as accumulation of the drug may occur, potentially increasing the risk of adverse effects.
- Regular monitoring of renal function may be necessary in such individuals.
- Patients with known hypersensitivity reactions to calcium dobesilate or any of its excipients should avoid its use.
- Due to insufficient data, use in pregnant or breastfeeding women should be carefully considered, and the potential benefits must outweigh the potential risks.
How it Works (Mechanism of Action)
Calcium dobesilate exerts its therapeutic effects primarily through its angioprotective and vasoprotective properties, targeting the microcirculation. It acts by reducing abnormally increased capillary permeability, thereby minimizing fluid and protein leakage from the capillaries into the surrounding tissues, which is a hallmark of microangiopathies and venous insufficiency. Concurrently, it enhances capillary resistance, making the small blood vessels less fragile and susceptible to damage. Beyond these direct effects on capillary integrity, calcium dobesilate has been shown to improve blood rheology by decreasing plasma viscosity and inhibiting erythrocyte aggregation, leading to better microcirculatory flow. It also exhibits anti-platelet aggregation properties, further contributing to improved blood flow in compromised microvessels. Additionally, calcium dobesilate may exert protective effects on endothelial cells, the cells lining blood vessels, and possesses antioxidant characteristics, which help to mitigate oxidative stress and inflammation within the vascular system. These multifaceted actions collectively contribute to the stabilization of microvascular function and the alleviation of symptoms associated with various vascular disorders.
Commercial Brands (Alternatives)
No other brands found for this formula.